100 related articles for article (PubMed ID: 32027302)
1. [Research Advance on Classic Wnt Pathway in Chronic Myelogenous Leukemia--Review].
Cao ZR; Chen XP; Hu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):350-353. PubMed ID: 32027302
[TBL] [Abstract][Full Text] [Related]
2. Volatile anesthetics sevoflurane targets leukemia stem/progenitor cells via Wnt/β-catenin inhibition.
Ruan X; Jiang W; Cheng P; Huang L; Li X; He Y; Mai M; Tan Z
Biomed Pharmacother; 2018 Nov; 107():1294-1301. PubMed ID: 30257344
[TBL] [Abstract][Full Text] [Related]
3. [Research Progress of β-catenin in Chronic Myelogenous Leukemia -Review].
Ding W; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):600-602. PubMed ID: 29665939
[TBL] [Abstract][Full Text] [Related]
4. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.
Schürch C; Riether C; Matter MS; Tzankov A; Ochsenbein AF
J Clin Invest; 2012 Feb; 122(2):624-38. PubMed ID: 22232214
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling.
Li Y; Hu J; Song H; Wu T
Biochem Biophys Res Commun; 2018 Nov; 505(3):858-864. PubMed ID: 30301525
[TBL] [Abstract][Full Text] [Related]
6. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.
Zhao C; Blum J; Chen A; Kwon HY; Jung SH; Cook JM; Lagoo A; Reya T
Cancer Cell; 2007 Dec; 12(6):528-41. PubMed ID: 18068630
[TBL] [Abstract][Full Text] [Related]
7. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
8. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
9. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
10. Potential role of Wnt/β-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between β-catenin and BCR-ABL.
Hu J; Feng M; Liu ZL; Liu Y; Huang ZL; Li H; Feng WL
Tumour Biol; 2016 Nov; ():. PubMed ID: 27817074
[TBL] [Abstract][Full Text] [Related]
11. [Effect of Quercetin on Wnt/β-Catenin Signal Pathway of K562 and K562R Cells].
Li W; Zhao Y; Qiu L; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1409-1415. PubMed ID: 31607291
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.
Nagao R; Ashihara E; Kimura S; Strovel JW; Yao H; Takeuchi M; Tanaka R; Hayashi Y; Hirai H; Padia J; Strand K; Maekawa T
Cancer Lett; 2011 Dec; 312(1):91-100. PubMed ID: 21906872
[TBL] [Abstract][Full Text] [Related]
13. Amide-linked local anesthetics preferentially target leukemia stem cell through inhibition of Wnt/β-catenin.
Ni J; Xie T; Xiao M; Xiang W; Wang L
Biochem Biophys Res Commun; 2018 Sep; 503(2):956-962. PubMed ID: 29932919
[TBL] [Abstract][Full Text] [Related]
14. Improving the solubility and antileukemia activity of Wnt/β-catenin signaling inhibitors by disrupting molecular planarity.
Ai Y; Sakamuru S; Imler G; Xia M; Xue F
Bioorg Med Chem; 2022 Sep; 69():116890. PubMed ID: 35777269
[TBL] [Abstract][Full Text] [Related]
15. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
[TBL] [Abstract][Full Text] [Related]
16. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of doxorubicin-transferrin conjugate is connected to the modulation of Wnt/β-catenin pathway in human leukemia cells.
Szwed M; Kania KD; Jozwiak Z
Leuk Res; 2015 Oct; 39(10):1096-102. PubMed ID: 26271413
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-370-3p inhibits cell proliferation and induces chronic myelogenous leukaemia cell apoptosis by suppressing PDLIM1/Wnt/β-catenin signaling.
Li LM; Luo FJ; Song X
Neoplasma; 2020 May; 67(3):509-518. PubMed ID: 31986893
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
